Panobinostat
- Generic Name
- Panobinostat
- Brand Names
- Farydak
- Drug Type
- Small Molecule
- Chemical Formula
- C21H23N3O2
- CAS Number
- 404950-80-7
- Unique Ingredient Identifier
- 9647FM7Y3Z
- Background
Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat is mar...
- Indication
Panobinostat is indicated in the treatment of multiple myeloma in combination with dexamethasone and bortezomib in patients who have received 2 previous treatment regimens including bortezomib and an immunomodulatory agent. This indication is approved by accelerated approval based on progression free survival as of February 23, 2015.
- Associated Conditions
- Refractory Multiple Myeloma
- Associated Therapies
- -
Panobinostat (LBH589) and Imatinib Mesylate in Treating Patients With Previously Treated Chronic Phase Chronic Myelogenous Leukemia
- First Posted Date
- 2008-05-29
- Last Posted Date
- 2014-08-15
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 9
- Registration Number
- NCT00686218
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸South Pasadena Cancer Center, South Pasadena, California, United States
🇺🇸Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
A Phase I Study of LBH589 (Panobinostat) in Combination With External Beam Radiotherapy for the Treatment of Prostate Cancer, Esophageal Cancer and Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-05-02
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 7
- Registration Number
- NCT00670553
- Locations
- 🇧🇪
Novartis Investigative Site, Liege, Belgium
Efficacy and Safety Study of Panobinostat in Participants With Metastatic Hormone Refractory Prostate Cancer
- First Posted Date
- 2008-04-28
- Last Posted Date
- 2021-06-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 35
- Registration Number
- NCT00667862
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸University of Maryland, Baltimore, Maryland, United States
🇺🇸Washington University, Saint Louis, Missouri, United States
LBH589 in Refractory Myelodysplastic Syndromes (MDS)
- First Posted Date
- 2008-01-15
- Last Posted Date
- 2021-11-22
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 26
- Registration Number
- NCT00594230
- Locations
- 🇺🇸
Consultants in Blood Disorders and Cancer, Louisville, Kentucky, United States
🇺🇸Northeast Georgia Medical Center, Gainesville, Georgia, United States
🇺🇸Oncology Hematology Care, Cincinnati, Ohio, United States
A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After Trastuzumab
- First Posted Date
- 2007-12-05
- Last Posted Date
- 2016-05-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 56
- Registration Number
- NCT00567879
- Locations
- 🇺🇸
University of California at Los Angeles, Los Angeles, California, United States
🇺🇸University of Pittsburgh Cancer Institute Dept of Magee Women's Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸VA Maryland Health Care Dept.of GreenbaumCancerCent(3), Baltimore, Maryland, United States
Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL)
- First Posted Date
- 2007-06-25
- Last Posted Date
- 2021-08-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 9
- Registration Number
- NCT00490776
- Locations
- 🇺🇸
Rush Presbyterian Hospital/St. Luke's Medical Center, Chicago, Illinois, United States
🇺🇸UCLA Medical Center School of Medicine/ Dpt of Hematology-Oncology, Los Angeles, California, United States
🇺🇸Florida Academic Dermatology Centers, Miami, Florida, United States
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
- First Posted Date
- 2007-01-23
- Last Posted Date
- 2021-08-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 139
- Registration Number
- NCT00425555
- Locations
- 🇨🇭
Novartis Investigative Site, Zürich, Switzerland
🇺🇸Emory University School of Medicine/Winship Cancer Institute Dept. of Hematology (2), Atlanta, Georgia, United States
🇺🇸Georgia Health Sciences University Dept.ofMedicalCollegeOfGeorgia, Augusta, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.